Skip to main content

AHFS November 2024 Update

This update contains 9 new monographs and 38 revised monographs.

New monographs: Axatilimab-csfr; Benzgalantamine Gluconate; Lazertinib Mesylate; Levamlodipine Maleate; Nemolizumab-ilto; Omidubicel-onlv; Palopegteriparatide; Seladelpar Lysine; Vorasidenib.

Revised monographs: Alpelisib; Alteplase; Atorvastatin Calcium; Belimumab; Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate; Brexanolone; Brincidofovir; Capecitabine; Capivasertib; Cidofovir; COVID-19 Vaccine, Adjuvanted (Novavax)(2024-2025 Formula); COVID-19 Vaccine, mRNA (Moderna) (2024-2025 Formula); COVID-19 Vaccine, mRNA (Pfizer-BioNTech); DULoxetine Hydrochloride; Efavirenz; Emtricitabine and Tenofovir Alafenamide Fumarate; Eplontersen Sodium; Influenza Vaccine Live Intranasal; Influenza Vaccine Recombinant; Insulin Human; Ponesimod; Remifentanil Hydrochloride; Ritonavir; Rosuvastatin Calcium; Simvastatin; Siponimod Fumarate; Smallpox (Vaccinia) Vaccine Live; Smallpox and Mpox Vaccine Live; Talazoparib Tosylate; Teclistamab-cqyv; Tecovirimat; Temozolomide; Tenapanor Hydrochloride (Phosphate-Removing Agent); Teriflunomide; Vaccinia Immune Globulin IV (Human); Vamorolone; Vandetanib; Zuranolone.